OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
Rhea-AI Summary
OSR Health (NASDAQ:OSRH) has received a Nasdaq Staff Delisting Determination dated August 19, 2026 and plans to submit a formal hearing request to the Nasdaq Independent Hearings Panel by August 26, 2026, while a trading suspension is expected on August 26.
According to OSR Health, under its April 2026 VXM01 Global Exclusive License Agreement, the company holds a $15 million Put Option exercisable against BCM Europe AG from October 29, 2026 at $10.00 per share. Management reports ongoing communication with BCM Europe’s Korean end investors regarding option settlement, and states that development at subsidiaries Woori IO and Darnatein will continue alongside preparations for a CVR registration statement.
Positive
- $15 million Put Option exercisable from October 29, 2026 at $10.00 per share
- Put Option cash proceeds exceed current market capitalization according to OSR Health
- Subsidiaries Woori IO and Darnatein continue development activities despite listing challenges
Negative
- Nasdaq Staff Delisting Determination received on August 19, 2026
- Expected trading suspension of OSRH shares on August 26, 2026
- OSR Health must seek Nasdaq hearing to argue for continued listing
News Explained
The potential $15 million liquidity comes with a conditional new-share issuance that could change existing holders' ownership.
OSR Health says it is preparing a Nasdaq hearing request for submission by
The arrangement links that cash to BCM Europe's investment in newly issued shares at
As of
Thus, the option is a potential liquidity source relative to the reported cash position, but its proceeds are not presently available because exercise has not been reported.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 19 | Nasdaq delisting notice | Negative | -13.2% | Delisting determination and scheduled suspension followed a negative 24-hour reaction. |
| Aug 11 | Listing status update | Negative | -6.0% | CEO addressed Nasdaq compliance concerns before a negative 24-hour reaction. |
| Aug 7 | Nasdaq communication clarification | Neutral | +1.6% | Company clarified Nasdaq did not endorse its CVR program. |
| Aug 3 | Clinical data publication | Positive | -0.4% | VXM01 clinical analysis was completed before a nearly flat reaction. |
| Jul 31 | CVR program update | Positive | +4.2% | Nasdaq communication addressed price adjustments for the shareholder CVR program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history showed three aligned and two divergent reactions; negative Nasdaq-related news was followed by negative reactions, while clinical data diverged.
Key Terms
put option financial
delisting determination regulatory
cvr financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Company details its Nasdaq hearing request, its
BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.
To OSR Health Shareholders:
I am aware that many of you are watching closely to see what comes next. I want to address some of your concerns directly and with specificity.
OSR Health's stock is showing resilience this morning after a difficult session yesterday. In our opinion, that resilience reflects something real: the conviction of shareholders who understand this Company and its potential.
WHAT IS HAPPENING AND WHAT WE ARE DOING
We received the Nasdaq Staff Delisting Determination on August 19, which we disclosed immediately, as required. We are now preparing our formal request for a hearing before the Nasdaq Independent Hearings Panel, which we plan to submit no later than August 26.
I want to be clear about what this hearing represents. It is a formal appeal before an independent Panel, in which we will present the case for OSR Health's continued listing based on documented evidence and a near-term compliance plan. We are approaching this hearing with the same diligence and preparation with which we have addressed our challenges over the past several months.
Our case to the Panel will rely on more than the extraordinary trading activity of August 17 and 18, although we believe that record speaks powerfully for itself. Our case will also rely on the fundamental value of what this company has built and on a realistic, near-term plan to demonstrate compliance.
THE PUT OPTION - A NEAR-TERM CATALYST
I want to speak plainly about our Put Option, because I believe the market has not fully appreciated what it represents.
As part of the VXM01 Global Exclusive License Agreement executed in April 2026, OSR Health holds a Put Option exercisable against BCM Europe AG, a Swiss life sciences investment firm backed by South Korean pharmaceutical investors, for
Respectfully, I ask you to consider what that means. BCM Europe agreed to invest in newly issued shares of our Company at
I am not in a position to predict when or how the market will close that gap. What I can confirm is this: the Put Option contractual right remains unchanged. It is legally defined and protected under the Global License Agreement. Our management and BCM Europe have been in active communication with BCM Europe's end investors in Korea regarding their capacity to accept and settle our exercise of the option in October. While we have determined that moving up the exercise date is not currently a practicable option, we confirm that the
For some additional context: at today's share price, the Company's entire market capitalization is smaller than the cash proceeds we are contractually entitled to receive from the exercise of this single option. We believe that disconnect, in time, will be corrected by the market.
OUR PIPELINE CONTINUES
Our listing status does not slow our business. Woori IO and Darnatein plan to continue their development activities, and we will provide business development updates from both subsidiaries as material developments warrant. OSR Health's mission - building an Innovation Headquarters for global healthcare - also continues forward in spite of our current challenges.
The period ahead is not without uncertainty. The trading suspension on August 26 will be a difficult moment for many of our shareholders, and I do not minimize that.
We are managing this situation proactively. We have a hearing to prepare, a registration statement to file for our CVR program, a Put Option to exercise, and a business to continue building. The work continues every day.
We will continue to update you at every meaningful milestone.
Sincerely,
Peter Hwang
Chief Executive Officer
OSR Health, Inc. (NASDAQ:OSRH)
About OSR Health, Inc.
OSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.com.
Investor Contact
OSR Health, Inc.
Investor Relations
ir@osr-health.com
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's planned Nasdaq hearing request, the BCM Europe AG Put Option, the CVR program and related S-1 registration, and subsidiary development activities. These statements involve risks and uncertainties - including the outcome of the Nasdaq Hearings Panel proceeding, BCM Europe AG's ability to satisfy its Put Option obligations, and other risks described in the Company's SEC filings - that may cause actual results to differ materially. The Company undertakes no obligation to update these statements except as required by law.
SOURCE: OSR Health, Inc.
View the original press release on ACCESS Newswire